HOUSE_OVERSIGHT_024846.jpg

1.24 MB
View Original

Extraction Summary

1
People
6
Organizations
1
Locations
0
Events
1
Relationships
5
Quotes

Document Information

Type: Market research report / financial analyst report
File Size: 1.24 MB
Summary

This document is page 30 of a Cowen Collaborative Insights market research report dated February 25, 2019. It analyzes the packaging and market positioning of four CBD brands: Lord Jones, CV Sciences (Plus CBD Oil), Papa & Barkley, and Reliva. The document bears the Bates stamp HOUSE_OVERSIGHT_024846, indicating it was obtained during a US House Oversight Committee investigation, though the specific page content relates strictly to commercial CBD products and contains no direct mention of Jeffrey Epstein.

People (1)

Name Role Context
Michael Cella Recipient/User
Report is watermarked as intended for 'michael.cella@cowen.com'

Organizations (6)

Name Type Context
Cowen
Financial services firm producing the report (Cowen Collaborative Insights)
Lord Jones
CBD brand analyzed in Figure 33
CV Sciences
CBD brand analyzed in Figure 34
Papa & Barkley
CBD brand analyzed in Figure 35
Reliva
CBD brand analyzed in Figure 36
House Oversight Committee
Implied by Bates stamp 'HOUSE_OVERSIGHT'

Locations (1)

Location Context
Address for CV Sciences, Inc. visible on bottle label: 2688 South Rainbow Blvd, Suite B, Las Vegas, NV 89146

Relationships (1)

Michael Cella Employee/Affiliate Cowen
Email address domain @cowen.com listed in sidebar watermark.

Key Quotes (5)

"Lord Jones Price Point Reflects Premium Positioning"
Source
HOUSE_OVERSIGHT_024846.jpg
Quote #1
"CV's Plus CBD Oil Competitively Positioned Within Premium"
Source
HOUSE_OVERSIGHT_024846.jpg
Quote #2
"Papa & Barkley Currently Offer Tinctures Only"
Source
HOUSE_OVERSIGHT_024846.jpg
Quote #3
"Reliva Tinctures Compete On Value"
Source
HOUSE_OVERSIGHT_024846.jpg
Quote #4
"This report is intended for michael.cella@cowen.com. Unauthorized redistribution of this report is prohibited."
Source
HOUSE_OVERSIGHT_024846.jpg
Quote #5

Discussion 0

Sign in to join the discussion

No comments yet

Be the first to share your thoughts on this epstein document